Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.

2019-04-05

Li, Na

McInerny, Simone

Zethoven, Magnus

Cheasley, Dane

Lim, Belle W X

Rowley, Simone M

Devereux, Lisa

Grewal, Norah

Ahmadloo, Somayeh

Byrne, David

Lee, Jue Er Amanda

Li, Jason

Fox, Stephen B

John, Thomas

Antill, Yoland

Gorringe, Kylie L

James, Paul A

Campbell, Ian G

RAD51C

breast cancer susceptibility

familial breast cancer

homologous recombination deficiency

triple-negative breast cancer

Journal Article

10.1093/jnci/djz045

Loss-of-fuction variants in RAD51C are associated with familial ovarian cancer, but its role in hereditary breast cancer remains unclear. The aim of this study was to couple breast tumor sequencing with case/control data to clarify the contribution of RAD51C to hereditary breast cancer. RAD51C was sequenced in 3080 breast cancer index cases that were negative in BRCA1/2 clinical tests and 4840 population-matched cancer-free controls. Pedigree and pathology data were analysed. Nine breast cancers and one ovarian cancer from RAD51C variant carriers were sequenced to identify bi-alleic inactivation of RAD51C, copy number variation, mutational signatures and the spectrum of somatic mutations in breast cancer driver genes . The promoter of RAD51C was analysed for DNA methylation. A statistically significant excess of loss of function variants were identified in 3080 cases (0.4%) compared with two among 4840 controls (0.04%; odds ratio=8.67, 95% confidence interval=1.89 to 80.52, P<.001) with over half of the carriers having no personal or family history of ovarian cancer. In addition, the association was highly statistically significant among cases with ER negative (P<.001) or triple-negative cancer (P<.001), but not in ER positive cases. Tumor sequencing from carriers confirmed bi-allelic inactivation in all the triple-negative cases and was associated with high HRD scores and mutational signature 3 indicating homologous recombination repair deficiency. This study provide evidence that germline loss-of-function variants of RAD51C are associated with hereditary breast cancer, particular triple-negative type. RAD51C-null breast cancers possess similar genomic and clinical features to BRCA1-null cancers and may also be vulnerable to DNA double-strand break inducing chemotherapies and PARP inhibitors.

link

Journal of the National Cancer Institute 2019; online first: 5 April

Journal of the National Cancer Institute